Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry.

Autor: Tsimafeyeu I; Kidney Cancer Research Bureau, Moscow, Russia.; Institute of Oncology, Hadassah Medical Moscow, Moscow, Russia., Shatkovskaya O; Department of Strategic Development and International Relations, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan., Krasny S; N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus., Nurgaliev N; Department of Urology, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan., Varlamov I; Department of Urology, Altai Regional Cancer Center, Barnaul, Russia., Petkau V; Out-Patient Department, Sverdlovsk Regional Oncological Dispensary, Ekaterinburg, Russia., Safina S; Chemotherapy Department, Republican Clinical Oncology Dispensary, Kazan, Russia., Zukov R; V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia., Mazhbich M; Department of Urology, Omsk Regional Cancer Center, Omsk, Russia., Statsenko G; Omsk Regional Cancer Center, Omsk, Russia., Varlamov S; Department of Urology, Altai Regional Cancer Center, Barnaul, Russia., Novikova O; Chemotherapy Department, Khabarovsk Regional Cancer Center, Khabarovsk, Russia., Zaitsev I; Department of Urology, Astrakhan Regional Cancer Center, Astrakhan, Russia., Moiseyev P; Organization of Anticancer Control, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus., Rolevich A; Laboratory of Oncourological Pathologies, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus., Evmenenko A; Department of the Organization of Anticancer Control, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus., Popova I; Department of Medical Oncology, National Medical Research Centre for Oncology, Rostov-on-Done, Russia., Kaidarova D; Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan., Vladimirova L; Department of Medical Oncology, National Medical Research Centre for Oncology, Rostov-on-Done, Russia.
Jazyk: angličtina
Zdroj: Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2021 Jun; Vol. 4 (3), pp. e1331. Date of Electronic Publication: 2020 Dec 25.
DOI: 10.1002/cnr2.1331
Abstrakt: Background: Real-world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous.
Aim: RENSUR3 registry study assessed real-world data on the use of therapies in mRCC and overall survival (OS) in Russia, Kazakhstan, and Belarus.
Methods: Patients were included in the retrospective multicenter registry study. To be eligible, patients were required to have mRCC diagnosed from January 2015 to January 2016. Anonymized data were collected through an online registry. The outcomes of interest were patient characteristics, treatment patterns, and OS.
Results: 1094 mRCC patients were identified. Mean age was 62.3 (SD, 11.2) years. Four hundred and forty-four (41%) patients were 65 years and older. Primary tumor has not been removed in 503 (46%) patients. Subtype of RCC based on WHO classification (clear-cell or other) has been reported in 402 (37%) patients. In total, 595 (54.4%) patients received systemic therapy for metastatic disease. 58% of elderly patients (≥65) were not treated compared to 37% of younger patients. Cytokines and targeted therapy were used in 298 (50.1%) and 297 (49.9%) of 595 treated patients, respectively. Median OS was 11.9 months (95% CI 10.9-12.9). The 1- and 3-year OS rates were 49.6% and 19.3%.
Conclusions: Half of patients received no systemic therapy or had only cytokines for mRCC in Russia, Kazakhstan, and Belarus, which doubtless negatively affected OS in this population. Novel therapies should be considered as life prolonging and a priority.
(© 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: